Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:02 2025-07-10 am EDT			5-day change	1st Jan Change
99.21 ^CHF	+1.70%		+0.79%	+11.85%

Jul. 09	Swiss Market Index Closes Higher; SGS Shares Down	MT
Jul. 09	Sironax grants Novartis exclusive option to acquire its brain delivery platform	RE

WRAPUP 5-Trump officials downplay court ruling that blocked sweeping tariffs

Published on 05/29/2025 at 14:56

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novartis AG

Swiss Market Index Closes Higher; SGS Shares Down	Jul. 09	MT
Sironax grants Novartis exclusive option to acquire its brain delivery platform	Jul. 09	RE
Sironax grants Novartis exclusive option to acquire its brain delivery platform while retaining rights to advance selected therapeutic assets	Jul. 09	RE
Europe rises despite new US tariff mayhem	Jul. 09	AN
Company earnings: key dates for next week	Jul. 09
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
Swiss Equities in the Green; Galderma Gains	Jul. 08	MT
Novartis wins approval for first malaria drug for newborns and babies	Jul. 08	RE
Global markets live: Apple, Honeywell Int., BP, Newmont, Nissan…	Jul. 08
Novartis wins approval for first malaria drug for newborns and babies	Jul. 08	RE
Novartis' Coartem Secures Swiss Approval as First Malaria Medicine for Newborns	Jul. 08	MT
Novartis Gets Swiss Approval for Malaria Drug for Infants	Jul. 08	MT
Novartis: pediatric antimalarial drug approved	Jul. 08	CF
Novartis gets Swissmedic approval for Coartem Baby as first malaria drug for newborns & young infants	Jul. 08	RE
Novartis' Malaria Treatment for Infants Receives Swissmedic Approval	Jul. 08	MT
Novartis receives approval for first malaria medicine for newborn babies and young infants	Jul. 08	DJ
Sector Update: Tech	Jul. 07	MT
Alphabet's Isomorphic Labs Readying to Test AI-Designed Drugs on People	Jul. 07	MT
GSK Finalizes Acquisition of Boston Pharmaceuticals' Liver Disease Drug Candidate	Jul. 07	MT
European shares fall as banks, mining stocks losses weigh	Jul. 04	RE
Swiss Market Index Closes Flat; Drugmakers Gain on US-Swiss Trade Deal Talks	Jul. 04	MT
NOVARTIS AG : Receives a Buy rating from Deutsche Bank	Jul. 04	ZD
European Equities Close Mostly Higher in Thursday Trading; EU Targets July 9 for US Trade Deal	Jul. 03	MT
Switzerland seeks trade deal with Trump without getting into EU bind	Jul. 03	RE

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (29.3%); - immunology (18.5%); - cardiovascular, renal and metabolic diseases (17%); - neuroscience (9.4%). The remaining net sales (25.8%) are from contract manufacturing of pharmaceutical products. At the end of 2024, Novartis AG had over 30 production sites worldwide. Net sales are distributed geographically as follows: Europe (30.9%), the United States (42%), Asia/Africa/Australasia (20%), Canada and Latin America (7.1%).

Employees

75,883

Sector

Pharmaceuticals

Calendar

Jul. 16 - Q2 2025 Earnings Release

More about the company